# US 2003/0216462 A1 · (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216462 A1
- Document ID: US20030216462A1
- Status: Published application
- Kind: A1
- Application number: 10/371,157
- Filed: 2003-02-24
- Published: 2003-11-20
- Earliest claimed: 2000-05-02
- Assignees: Sugen, Inc.
- Inventors: Chung Chen Wei; Peng Cho Tang
- Web page: https://patentgrep.com/patent/US20030216462A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/34: in position 2
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to (2-oxindol-3-ylidenyl)acetic acid derivatives which modulate the activity of protein kinases and are therefore useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

## Claims

### Claim 1

A compound of Formula (I):
25
wherein:
X is selected from the group consisting of oxygen, sulfur and —NH—;
Y is selected from the group consisting of carbon and nitrogen, it being understood that, when Y is nitrogen, R5 does not exist;
n is 0, 1, 2 or 3;
R1 is selected from the group consisting of hydrogen and alkyl;
R2 is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, trihaloalkyl, hydroxy, alkoxy, —C(O)R16, —NR17R18, and —(CH2)rR19;
R3 and R4 are independently selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, —NR17R18, —C(O)R16, aryl, 6-member ring heteroaryl, —S(O)2NR17R18, NR17S(O)2R18, —NR17C(O)R18, and —NR17C(O)OR18;
R5 is selected from the group consisting of hydrogen, alkyl, halo, hydroxy, and alkoxy;
when n is 0 and X is oxygen or sulfur, R6 is selected from the group consisting of hydrogen, alkyl, and aryl;
when n is 0 and X is nitrogen, R6 is selected from the group consisting of hydrogen, alkyl, and aryl or R6 combines with X to form a heteroalicyclic ring;
when n is 1, 2 or 3, R6 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, —C(O)R16, and —NR17R18;
R7 is selected from the group consisting of
26
wherein:
B1, B2, B3, B4 and B5 are carbon, or
one of B1, B2, B3, B4 or B5 is nitrogen, the others being carbon, or
B1 and B2 or B2 and B3 or B3 and B4 are nitrogen, the others being carbon, or
B1 and B3 or B32 and B4 and B5 are nitrogen, the others being carbon, or
B1, B3 and B5 are nitrogen, the others being carbon;
R8, R11 and R12 are independently selected from the group consisting of hydrogen, alkyl, trihalomethyl, hydroxy, alkoxy, halo, —C(O)R16, —(CH2)rR19, and —NR17R18;
R9 and R10 are independently selected from the group consisting of hydrogen, alkyl, trihalomethyl, hydroxy, alkoxy, halo, —C(O)R16, —(CH2)rR19, and —NR17R18; or
R9 and R10 may combine to form a —(CH2)3— or a —(CH2)4— group; it being understood that, when any of B1, B2, B3, B4 or B5 is nitrogen, R8, R9, R10, R11 or R12, respectively, does not exist;
D1 is selected from the group consisting of —NR20—, oxygen, or sulfur;
D2, D3 and D4 are independently selected from the group consisting of carbon and nitrogen, it being understood that, when D2, D3 or D4 is nitrogen, R13, R14 or R15, respectively, does not exist;
R15 is independently selected from-the group consisting of hydrogen, alkyl, alkoxy, halo, —(CH2) R21, and —C(O)R16;
R13 and R14 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, halo, —(CH2)sR21, and —C(O)R16; or
R13 and R14 may combine to form a —(CH2)4— group;
R16 is selected from the group consisting of hydrogen, hydroxy, alkoxy, and —NR17R18;
R17 and R18 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, and heteroaryl; or
R17 and R18 may combine to form a group selected from the group consisting of —(CH2)4—, —(CH2)5—, —(CH2)2O(CH2)2—, and —(CH2)2N(R20)(CH2)2—;
R19 is selected from the group consisting of hydroxy, alkoxy, —NR17R18, and —C(O)R16, wherein R16, R17 and R18 are defined as above;
R20 is selected from the group consisting of hydrogen and alkyl;
R21 is selected from the group consisting of hydroxy, alkoxy, —NR17R18, and —C(O)R16, wherein R16, R17 and R18 are defined as above; and,
r and s are independently 1, 2 or 3; or,
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein R1 is hydrogen.

### Claim 3 (depends on 2)

The compound or salt of claim 2, wherein R2 and R5 are hydrogen.

### Claim 4 (depends on 3)

The compound or salt of claim 3, wherein R7 is
27
where B1, B2, B3, B4 and B5 are carbon.

### Claim 5 (depends on 4)

The compound or salt of claim 4, wherein R8, R9, R10, R11 and R12 are independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, halo, trihalomethyl and —NR17R18.

### Claim 6 (depends on 3)

The compound or salt of claim 3, wherein R7 is
28

### Claim 7 (depends on 6)

The compound or salt of claim 6, wherein:
D is —NH—; and,
D2, D3 and D4 are carbon.

### Claim 8 (depends on 7)

The compound or salt of claim 7, wherein R13 and R15 are independently selected from the group consisting of hydrogen, lower alkyl and halo.

### Claim 9 (depends on 8)

The compound or salt of claim 8, wherein R14 is selected from the group consisting of hydrogen and —(CH2)sR21.

### Claim 10 (depends on 1)

The compound or salt of claim 1, wherein:
X is oxygen;
n is, 0; and,
R6 is selected from the group consisting of hydrogen and lower alkyl.

### Claim 11 (depends on 4)

The compound or salt of claim 4, wherein:
X is oxygen;
n is 0; and
R6 is selected from the group consisting of hydrogen and lower alkyl.

### Claim 12 (depends on 7)

The compound or salt of claim 7, wherein:
X is oxygen;
n is 0; and
R6 is selected from the group consisting of hydrogen and lower alkyl.

### Claim 13 (depends on 1)

The compound or salt of claim 1, wherein
X is —NH—;
n is 0;
R6 is phenyl; and
R8, R9, R10, R11 and R12 are independently selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkoxy, trihalomethyl, —(CH2)sNR17R18 and —NR17R18.

### Claim 14 (depends on 4)

The compound or salt of claim 4, wherein:
x is —NH—;
n is 0;
R6 is phenyl; and
R8, R9, R10, R11 and R12 are independently selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkoxy, trihalomethyl, —(CH2)sNR17R18 and —NR17R18.

### Claim 15 (depends on 7)

The compound of claim 7, wherein:
X is —NH—;
n is 0;
R6 is phenyl; and
R8, R9, R10, R11 and R12 are independently selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkoxy, trihalomethyl, —(CH2)sNR17R18 and —NR17R18.

### Claim 16 (depends on 1)

The compound or salt of claim 1, wherein:
X is —NH—,
n is 2, 3 or 4; and
R6 is —NR17R18.

### Claim 17 (depends on 16)

The compound or salt of claim 16, wherein:
R17 and R18 are independently selected from the group consisting of hydrogen, lower alkyl, and, combined to form —(CH2)4—, —(CH2)5—, —(CH2)2O(CH2)2—, and —(CH2)2N(CH3)(CH2)2.

### Claim 18 (depends on 7)

The compound of claim 7, wherein:
X is —NH—,
n is 2, 3 or 4; and,
R6 is —NR17R16.

### Claim 19 (depends on 1)

A pharmaceutical composition, comprising a compound or salt of claim 1; and a pharmaceutically acceptable carrier or excipient.

### Claim 20 (depends on 1)

A method for treating a protein kinase related disorder in an organism comprising administering to said organism a therapeutically effective amount of a compound or salt of claim 1.

### Claim 21 (depends on 20)

The method of claim 20 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

### Claim 22 (depends on 20)

The method of claim 20 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

### Claim 23 (depends on 20)

The method of claim 20 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

### Claim 24 (depends on 20)

The method of claim 20 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Hippel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

### Claim 25 (depends on 20)

The method of claim 20 wherein said organism is a human.
